Nanobiotix S.A.

Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX's lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900's platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal.

seekingalpha.com - 2026-06-25 05:46:32

Nanobiotix is evolving into a capital-light, milestone- and royalty-driven oncology platform with JNJ-1900 at its core. JNJ-1900, now led by Johnson & Johnson, targets radioenhancement across multiple solid tumors, with a $2.6B potential milestone structure and double-digit royalties. Recent financing and a May 2026 equity raise extend NBTX's cash runway through 2029, shifting clinical and operational risk to J&J.

seekingalpha.com - 2026-06-12 16:58:37

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

globenewswire.com - 2026-06-05 16:15:00

PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first quarter of 2026.

globenewswire.com - 2026-06-02 16:30:00

PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors.

globenewswire.com - 2026-06-02 02:30:00

PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “Closing”) of its global offering (the “Global Offering”), including in respect of the earlier total exercise by the underwriters of their option (the “Option”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “Additional ADSs”).

globenewswire.com - 2026-05-26 16:44:00

PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces that the underwriters of its previously announced global offering (the “Global Offering”) have fully exercised their option to purchase 33,805 additional new ordinary shares in the form of additional American Depositary Shares (the “Additional ADSs”) (the “Option”). Each Additional ADS represents one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company and the offering price of $38.98 per Additional ADS corresponds to a price of €33.60 per Ordinary Share (on the basis of an exchange rate of $1.16 = €1.00). The Additional ADSs will be delivered concurrently with the closing of the Global Offering which is expected to occur on May 26, 2026.

globenewswire.com - 2026-05-22 16:15:00

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the pricing of its previously announced global follow-on offering, consisting of (i) a public offering of 225,373 American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $38.98 per ADS, and (ii) an offering of (a) 1,959,289 Ordinary Shares and (b) 345,099 pre-funded warrants to subscribe for one Ordinary Share each (the “PFW”), exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”), and certain other countries (excluding the United States and Canada) (the “International Offering”, together with the U.S. Offering, the “Global Offering”), at an offering price of €33.60 per Ordinary Share and €33.57 per PFW.

globenewswire.com - 2026-05-21 10:57:00

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).

globenewswire.com - 2026-05-21 09:30:00

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.

globenewswire.com - 2026-05-21 02:30:00

PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately $87 million) consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares (the “PFW”), exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”), and certain other countries (excluding the United States and Canada) (the “International Offering”). The U.S. Offering and the International Offering are referred to, together, as the “Global Offering”. The number of ADSs and Ordinary Shares issued in the Global Offering may be increased in the event of significant demand.

globenewswire.com - 2026-05-20 18:19:00

Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch biotech stock is flying.

investors.com - 2026-05-20 08:00:31

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting

globenewswire.com - 2026-05-17 10:15:00

PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study.

globenewswire.com - 2026-05-04 17:29:00

Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The

defenseworld.net - 2026-04-24 04:22:52

Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (“LNP-DNA”) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer Data presented at the 2026 Annual Meeting of the American Association for Cancer Research PARIS and CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of new preclinical data evaluating its Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA (“LNP-DNA”) at the 2026 Annual Meeting of the American Association for Cancer Research (AACR).

globenewswire.com - 2026-04-20 02:30:00

Nanobiotix (NASDAQ: NBTX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Insider and Institutional Ownership 38.8% of Nanobiotix shares

defenseworld.net - 2026-04-17 01:28:57